HeartFlow, Inc. (HTFL)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
$48.91-1.61%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-09-04
Research Workspace
Put HTFL beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRanks in the weakest quality tier of its industry — roughly the bottom 43%, softest on share dilution.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 49% in its worst 12-month stretch.
View RiskHTFL's growth trajectory relies on its ability to sustain revenue growth after recent guidance raises. Revenue surged 48% year over year, and the latest quarter beat expectations. It trades at 20× price-to-sales versus a peer median of 2×, indicating that the price reflects less growth than forecasted. If HTFL cuts guidance after recently raising it, that could damage credibility and lead to a significant stock drop. Peer multiples imply a price about 40% below where it trades (it looks expensive on this basis). Our read remains intact.
Trailing returns as of 2026-09-04. HTFL is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 9 analysts currently covering HTFL (as of Sep 2026).
Based on 6 Wall Street analysts offering 12-month price targets for HTFL in the last 4 months.
Continue this research
Compare HTFL with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| HTFL Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Technology — fair value, gap to price, and forward P/E.
Compare the value case
Put HTFL next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Increase annual revenue guidance to $246M-$250M
Q2 EPS miss raises concerns about revenue growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $48.91
The last 12 months of price, then the range of analyst 12-month targets from today’s $48.91.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Raised outlook supports revenue growth objectives.
Advances: Increase annual revenue guidance to $246M-$250M
Q2 beat and guidance raise support revenue growth objective.
Advances: Increase annual revenue guidance to $246M-$250M
Revenue surge supports growth objective and overall thesis.
Advances: Increase annual revenue guidance to $246M-$250M
Increased revenue guidance aligns with growth objectives.
Advances: Increase annual revenue guidance to $246M-$250M
Earnings call details confirm revenue growth.
Advances: Increase annual revenue guidance to $228M-$232M
Earnings beat supports revenue growth objective.
Earnings beat but stock drop indicates market concerns.